## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 3.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. FDA Flags Medtronic Heart Catheter Recall As Most Serious Safety Risk**
- Source: Benzinga | 20251224T140848 | Bearish | Relevance: 100%
- The U.S. Food and Drug Administration has issued a Class I recall, its most serious category, for certain Medtronic Left Heart Vent Catheters due to safety concerns. These catheters, used during cardiopulmonary bypass, may fail to maintain their shape, potentially causing tissue abrasion, perforation, or even death. Medtronic has reported three serious injuries related to this issue and no deaths as of July 28.

**2. FDA posts Class I recall notice about Medtronic heart vent catheters**
- Source: MedTech Dive | 20251223T153953 | Bearish | Relevance: 100%
- The FDA has issued a Class I recall notice for Medtronic's DLP Left Heart Vent Catheters due to issues with shape retention and perforation injuries. Medtronic had previously initiated a customer notification and quarantine of the affected lots after receiving 41 complaints, including three serious perforation injuries. The company has since corrected the issue for newly manufactured lots, but acknowledged limited product availability.

**3. Medtronicâ€™s diabetes spinoff MiniMed files for IPO**
- Source: MedTech Dive | 20251222T160446 | Somewhat-Bearish | Relevance: 100%
- Medtronic's diabetes spinoff, MiniMed, has filed for an initial public offering, despite reporting a $198 million loss on sales of $2.72 billion in its 2025 fiscal year. The company aims to leverage its broad portfolio of insulin pumps and glucose sensors to generate more revenue per customer, positioning itself against more specialized competitors. However, MiniMed faces challenges with the profitable manufacturing and scaling of its Simplera CGM sensor, which has led to significant charges and a decline in U.S. insulin pump sales.

**4. Medtronic launches a state-of-the-art Mobile Surgi-skill Lab to democratize access to advanced skill development for young surgeons across India**
- Source: Tribune India | 20251224T103828 | Bullish | Relevance: 100%
- Medtronic has launched a Mobile Surgi-skill Lab in India to bring advanced training in minimally invasive surgery to healthcare professionals in underserved tier 2 and 3 cities. This initiative aims to bridge the skill gap, elevate surgical standards, and improve patient outcomes by providing world-class training directly to medical colleges and hospitals. The lab features state-of-the-art simulations and a comprehensive curriculum, with plans to visit 10 tier 2 cities in the next year.

**5. Exchange Traded Concepts LLC Sells 113,677 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251224T091443 | Somewhat-Bullish | Relevance: 100%
- Exchange Traded Concepts LLC significantly reduced its stake in Medtronic PLC by 54.4% in the third quarter, selling 113,677 shares while retaining 95,431 shares valued at approximately $9.09 million. Medtronic reported strong quarterly earnings, beating expectations with an EPS of $1.36 and revenue of $8.96 billion, and announced a quarterly dividend of $0.71 per share. The company maintains a consensus analyst rating of "Moderate Buy" with an average price target of $109.94.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.7x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.73 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $124.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.73 |
| Forward P/E | 15.9 |
| Current P/E | 17.2 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.2% to -2.6% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.59), momentum weakening. RSI neutral at 42. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.64% (CS: 16) | Weak |
| RSI_14 | 41.7 | Neutral |
| MACD Histogram | -0.59 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.066x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.26
- **Stop Loss:** $94.24 (3.1% risk)
- **Target:** $100.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 397
- **Position Value:** $38,612.22
- **Portfolio %:** 38.61%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*